argenx SE (ARGX)

NASDAQ: ARGX · Real-Time Price · USD
767.00
-1.00 (-0.13%)
At close: Sep 9, 2025, 4:00 PM
757.50
-9.50 (-1.24%)
After-hours: Sep 9, 2025, 6:02 PM EDT
-0.13%
Market Cap46.82B
Revenue (ttm)3.12B
Net Income (ttm)1.28B
Shares Out 61.17M
EPS (ttm)18.75
PE Ratio36.57
Forward PE34.44
Dividendn/a
Ex-Dividend Daten/a
Volume345,824
Open762.39
Previous Close768.00
Day's Range757.90 - 769.22
52-Week Range510.06 - 769.22
Beta0.00
AnalystsStrong Buy
Price Target765.72 (-0.17%)
Earnings DateOct 30, 2025

About ARGX

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2017
Employees 1,599
Stock Exchange NASDAQ
Ticker Symbol ARGX
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 19 analysts, the average rating for ARGX stock is "Strong Buy." The 12-month stock price target is $765.72, which is a decrease of -0.17% from the latest price.

Price Target
$765.72
(-0.17% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

argenx SE (NASDAQ:ARGX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Karl Gubitz - Chief Financial Officer Conference Call Participants S...

1 day ago - Seeking Alpha

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Other symbols: BBHBMRNCYTKIBBXBI
6 days ago - CNBC Television

argenx to Present at Upcoming Investor Conferences

August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...

12 days ago - GlobeNewsWire

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE ARGX stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab)...

14 days ago - Benzinga

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG

Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegati...

15 days ago - GlobeNewsWire

argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

August 19, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today a...

21 days ago - GlobeNewsWire

argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis

Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life

4 weeks ago - GlobeNewsWire

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Insmed, Intuitive Surgical, and IDEXX Laboratories were top contributors, driven by strong drug pipelines, innovation, and robust financial results. We exited UnitedHealth Group due to earnings misses...

4 weeks ago - Seeking Alpha

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

5 weeks ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

5 weeks ago - CNBC Television

argenx SE (ARGX) Q2 2025 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations Karen Masse...

5 weeks ago - Seeking Alpha

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS foll...

5 weeks ago - GlobeNewsWire

argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025

July 24, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ann...

6 weeks ago - GlobeNewsWire

FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls

Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting system for Vyvgart Hytrulo (efgartigimod alf...

2 months ago - Benzinga

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART ® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the l...

2 months ago - GlobeNewsWire

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in auto...

3 months ago - GlobeNewsWire

argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today anno...

3 months ago - GlobeNewsWire

argenx Announces Results of Annual General Meeting of Shareholders

May 28, 2025 – 10:01 PM C ET

3 months ago - GlobeNewsWire

Argenx Q1 Earnings: Less Than Perfect Report Gets Punished

Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the M...

4 months ago - Seeking Alpha

argenx SE (ARGX) Q1 2025 Earnings Call Transcript

argenx SE (NASDAQ:ARGX) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeir...

4 months ago - Seeking Alpha

argenx Reports First Quarter 2025 Financial Results and Provides Business Update

$790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opin...

4 months ago - GlobeNewsWire

argenx to Present at BofA Securities 2025 Health Care Conference

May 6, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...

4 months ago - GlobeNewsWire

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

May 1, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today annou...

4 months ago - GlobeNewsWire

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ...

4 months ago - GlobeNewsWire

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase...

5 months ago - Benzinga